Patents by Inventor Ik-Jae Moon

Ik-Jae Moon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7498313
    Abstract: The present application describes a large circular target-specific antisense molecule that is effective in ablating RNA and protein expression. The large circular antisense molecule is used to treat any human disease in which modulation of gene expression can be beneficial to intervene in the disease initiation and progression.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: March 3, 2009
    Assignee: Welgene, Inc.
    Inventors: Jong-Gu Park, Ik-Jae Moon
  • Patent number: 7420050
    Abstract: The present application describes a purified covalently closed antisense molecule, which specifically inhibits expression of TGF-?.
    Type: Grant
    Filed: December 30, 2002
    Date of Patent: September 2, 2008
    Assignee: Welgene Pharmaceuticals, Inc.
    Inventors: Jong-Gu Park, Ik-Jae Moon, Young-Kook Choi, Kwankyu Park
  • Patent number: 7297759
    Abstract: The present application discloses a transfection effective carrier polypeptide comprising derivatives of HIV Tat peptide.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: November 20, 2007
    Assignee: Welgene, Inc.
    Inventors: Jong-Gu Park, Ik-Jae Moon, Young-Cheol Kim
  • Publication number: 20030216296
    Abstract: The present application discloses a transfection effective carrier polypeptide comprising derivatives of HIV Tat peptide.
    Type: Application
    Filed: January 28, 2003
    Publication date: November 20, 2003
    Inventors: Jong-Gu Park, Ik-Jae Moon, Young-Cheol Kim
  • Publication number: 20030165892
    Abstract: The present invention provides a high throughput system for functional genomics using a unigene antisense library comprising LC-antisense compounds. The antisense compounds were specific and effective for the elimination of target mRNA. Thus, the system of the present invention is used as temporary knock-down system to unveil functions of genes critical for diseases. The system of the present invention can be adopted not only for functional genomics but also for effectively validating target for antisense or other molecular therapeutics against various malignancies, infections, and other diseases by blocking specific genes involved in the disease.
    Type: Application
    Filed: May 15, 2002
    Publication date: September 4, 2003
    Applicant: WELGENE PHARMACEUTICALS, INC.
    Inventors: Jong-Gu Park, Ik-Jae Moon, Yun-Han Lee
  • Publication number: 20030153075
    Abstract: The present application describes a purified covalently closed antisense molecule, which specifically inhibits expression of TGF-&bgr;.
    Type: Application
    Filed: December 30, 2002
    Publication date: August 14, 2003
    Inventors: Jong-Gu Park, Ik-Jae Moon, Young-Kook Choi, Kwankyu Park
  • Publication number: 20020182181
    Abstract: The present application describes a large circular target-specific antisense molecule that is effective in ablating RNA and protein expression. The large circular antisense molecule is used to treat any human disease in which modulation of gene expression can be beneficial to intervene in the disease initiation and progression.
    Type: Application
    Filed: January 30, 2002
    Publication date: December 5, 2002
    Applicant: WELGENE, INC.
    Inventors: Jong-Gu Park, Ik-Jae Moon
  • Publication number: 20020168631
    Abstract: The present invention provides a high-throughput system for functional genomics using a random gene unidirectional antisense library comprising LC-antisense compounds. The antisense compounds were specific and effective for the elimination of target mRNA. Thus, the system of the present invention may be effectively used as temporary knock-down system to unveil functions of genes critical for diseases. The system of the present invention can be adapted not only for functional genomics but also for effectively validating target for antisense or other molecular therapeutics against various malignancies, infections, and other diseases by blocking specific genes involved in the disease.
    Type: Application
    Filed: March 8, 2002
    Publication date: November 14, 2002
    Applicant: WELGENE, INC.
    Inventors: Jong-Gu Park, Ik-Jae Moon, Yun-Han Lee